Different tumors have different characteristics and have very different levels of sensitivity to chemotherapy. Unlike chemotherapy-sensitive tumors such as lymphoma and choriocapillary epithelial carcinoma, prostate cancer is currently recognized as a chemotherapy-insensitive tumor. Currently, the main prostate chemotherapy drug used in clinical practice is docetaxel (Tysodex). Studies have shown that docetaxel can prolong the survival of hormone-refractory prostate cancer, so chemotherapy can be considered for hormone-refractory prostate cancer in clinical practice. However, due to its less than significant efficacy, chemotherapy ranks relatively low on the list of all available treatment options for prostate cancer.